Revvity, Inc. RVTY
Nov 12, 2026, 2:26 PM EST
- YTD
- +63.21%
- 1 year
- +67.75%
- Market cap
- 17.63B
- Revenue (ttm)
- 2.94B
- Profit margin
- 8.61%
- EPS (ttm)
- 2.25
- Shares out
- 111.59M
- P/E ratio
- 70.19
- Forward P/E
- 26.54
- Dividend
- 0.28 (0.17%)
- Ex-dividend date
- Jan 21, 2027
- YTD return
- +63.21%
- 1-year return
- +67.75%
- Volume
- 851.99K
- Avg volume
- 1.91M
- Open
- 156.51
- Previous close
- 158.25
- Day's range
- 153.04 – 159.36
- 52-week range
- 82.26 – 165.78
- Beta
- 1.09
- Analysts
- Buy
- Price target
- 171.07 (+8.3%)
- Earnings date
- Feb 1, 2027
5D +7.04 (+4.67%)
Key statistics
- Enterprise value
- 19.96B
- PEG ratio
- 0.98
- Price / sales
- 6.00
- Price / book
- 2.43
- Dividend yield
- 0.18%
- Payout ratio
- 13.40%
- Revenue growth
- 4.30%
- Free cash flow
- 626.77M
- Total cash
- 592.80M
- Total debt
- 2.77B
- Return on equity
- 3.45%
- Short % of float
- 8.76%
- 50-day average
- 148.77
- 200-day average
- 113.36
Analyst view
Consensus: buy
- Target (low)
- 122.00
- Target (mean)
- 171.07
- Target (high)
- 200.00
- Strong buy0
- Buy6
- Hold11
- Sell0
- Strong sell1
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 1.62.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Jan 4, 2027 | 1.61 | — | — | — |
| Nov 3, 2026 | Oct 4, 2026 | 1.30 | 1.38 | +0.08 | +6.15% |
| Aug 4, 2026 | Jul 5, 2026 | 1.21 | 1.41 | +0.20 | +16.53% |
| May 5, 2026 | Apr 5, 2026 | 1.02 | 1.06 | +0.04 | +3.92% |
| Feb 2, 2026 | Dec 28, 2025 | 1.57 | 1.70 | +0.13 | +8.28% |
| Oct 27, 2025 | Sep 28, 2025 | 1.14 | 1.18 | +0.04 | +3.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 4, 2026 | TD Cowen | main | Buy | Buy |
| Nov 4, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 4, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- revvity.com
News
ELV or RVTY: Which Is the Better Value Stock Right Now?
All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy
Madison Mid Cap Fund Q3 2026 Portfolio Activity JP Morgan Maintains Neutral on Revvity, Raises Price Target to $160
TD Cowen Maintains Buy on Revvity, Raises Price Target to $185
Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $175
RBC Capital Maintains Sector Perform on Revvity, Raises Price Target to $172
Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $180
Revvity Stock Hits 52-Week High - Here's Why
Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday
Your note
Sign in to keep a note on RVTY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT PETER | Director | Stock Award(Grant) | May 6, 2026 | 28,293 |
| CHAPIN SAMUEL R. | Director | Stock Award(Grant) | May 6, 2026 | 22,676 |
| GOLDBERG JOEL S | General Counsel | Stock Gift | Aug 13, 2026 | 105,223 |
| KRAKOWIAK MAXWELL | Chief Financial Officer | Sale | Sep 20, 2026 | 14,781 |
| MICHAS ALEXANDROS P | Director | Stock Gift | Aug 24, 2026 | 0 |
| MICHAS ALEXIS P | Director | Sale | Aug 26, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.37% | 18,261,177 | 2.89B | Jun 29, 2026 |
| Jupiter Topco LLC | 7.74% | 8,637,614 | 1.37B | Jun 29, 2026 |
| Edgepoint Investment Group Inc. | 7.66% | 8,544,479 | 1.35B | Jun 29, 2026 |
| Blackrock Inc. | 6.86% | 7,658,369 | 1.21B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 7,300,973 | 1.16B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.96% | 5,530,850 | 875.04M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 10.20% | 11,379,930 | 1.80B | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 4.33% | 4,828,680 | 763.95M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 3,545,122 | 560.87M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 2,890,294 | 457.27M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Value Equity Trust | 2.41% | 2,694,775 | 426.34M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 2,557,796 | 404.67M | Jun 29, 2026 |
